Skip to main content
. 2018 Mar 26;128(5):1807–1819. doi: 10.1172/JCI99088

Figure 4. PAI1 mediates mast cell infiltration and increased fibroblast mast cell adhesion.

Figure 4

(A) Quantification of migrating mast cells into buffer or recombinant PAI1–containing media in a Transwell assay (n = 5). Quantification adherent mast cells on newborn dermal fibroblasts after (B) recombinant PAI1 treatment of fibroblast–mast cell cocultures (n = 4) and (C) pretreatment of fibroblasts with buffer, recombinant PAI1, and RGD peptide (n = 3). (D) Immunostaining for surface-bound vitronectin after treatment of fibroblasts with buffer or recombinant PAI1 (n = 3). Scale bar: 50 μm. (E) Quantification of adherent mast cells after pretreatment of fibroblasts with buffer or recombinant PAI1 in the absence or presence of FAK inhibitor (FAK inh) (n = 3). (F) Immunostaining of ICAM1 expression after recombinant PAI1 treatment of fibroblasts in the absence or presence of FAK inhibitor (n = 3). Scale bar: 50 μm. (G) Quantification of adherent mast cells after pretreatment of fibroblasts with buffer or recombinant PAI1 followed by incubation with ICAM1 inhibitor (ICAM1 inh) or LDV peptide, or with mast cells (MCs) preincubated with LDV peptide (n = 3). Data represent the mean ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001, by Student’s t test (A and B) and 1-way ANOVA followed by Tukey’s post hoc analysis (C, E, and G).